Investor Presentation - First Six Months of 2021
111
Investor presentation
First six months of 2021
North America Operations at a glance.
NAO
Diabetes trend in population
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
Million
DKK
billion
First half of 2021
70
13%
600
70%
Total GLP-13
Sales
(mDKK)
15,850
Growth²
24%
60
18%
500
60%
Long-acting insulin
3,369
(13%)
50
50%
Premix insulin5
275
2%
400
36%1
GLP-1
WA
40
Fast-acting insulin
3,300
(8%)
40%
Human insulin
739
30
56
48
20
10
0
2019
56
63
83
300
(11%)
30%
Total insulin
7,683
(11%)
2%1
Insulin
200
Other Diabetes care?
492
20%
(8%)
Diabetes care
24,025
9%
100
11%1
OAD 10%
Obesity care8
2,046
27%
0
0%
May
2030
2045
2016
Population with diabetes
Diabetes growth rate
GLP-1 MS
Insulin MS
May
2021
OAD MS
Diabetes & Obesity
26,071
11%
care
Biopharm⁹
Total
3,790
12%
29,861
11%
International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 9th Edition 2019
1 CAGR calculated for 5-year period
Competitor insulin value market shares, as of May 2021: Novo Nordisk 42%,
Eli Lilly 30% and Sanofi 27%; Competitor GLP-1 value market shares, as of
May 2021: Novo Nordisk 51%, Eli Lilly 44% and AstraZeneca 5%
OAD: Oral anti-diabetic; MS: Market share; Source: IQVIA MAT, May 2021
value figures
2 At constant exchange rates; 3 Comprises Victoza®, Ozempic®, and RybelsusⓇ;
4 Comprises TresibaⓇ, XultophyⓇ and LevemirⓇ; 5 Comprises NovoMix®;
6 Comprises FiaspⓇ and NovoRapidⓇ; 7 Comprises Novo NormⓇ and needles; 8
Comprises SaxendaⓇ and WegovyTM 9 Comprises primarily NovoSeven®,
NovoEight® Esperoct®, NovoThirteen®, Refixia®, Norditropin®, VagifemⓇ and
Activelle®View entire presentation